UPDATE: 30th June 2026
The ongoing Bundibugyo ebolavirus (BDBV) outbreak is a stark reminder that the global threat landscape is dynamic and unpredictable. It shows that future infectious disease and pandemic risks cannot be fully anticipated and that preparedness must extend within and across viral families, including those that are rare or historically neglected.
Despite significant progress made since the 2014–2016 Ebola outbreak, this BDBV outbreak exposes persistent gaps in research and development, limited surge capacity, and the absence of ready‑to‑deploy medicines, vaccines or diagnostics – as set out in the 100 Days Mission BDBV tracker. These weaknesses slow our ability to respond at scale. Africa CDC and WHO’s joint continental preparedness and response plan demonstrates strong regional leadership and provides an important foundation for coordinated action. We also welcome the recent commitment by G7 leaders to a unified response to BDBV, as well as the forthcoming G20 discussions in October, which together signal growing political momentum. This creates a critical window to convert political attention into sustained, practical action.
The UN High‑Level Meeting Political Declaration on Pandemic Prevention, Preparedness, and Response (PPPR) should recognise BDBV as a clear example of why preparedness must be strengthened across emerging and re‑emerging pathogens. It should broaden commitment to support and fund the necessary elements to accelerating the current response to save lives quickly, mitigate economic disruption, and make innovations accessible, while aligning on new multilateral goals and funding requests that enable the development, authorisation, manufacturing and equitable delivery of diagnostics, therapeutics and vaccines.. This should include access conditions built into the R&D process as a key design feature, not an afterthought, immediate access to pipeline candidates for clinical trials, and robust post-trial access commitments. As reminded by the 100 Days Mission, this is urgent and such commitments are critical to translate political intent into practical action and financing. We must ensure systems and funding mechanisms are in place to rapidly generate evidence about and scale new tools for current and future outbreaks. We stand ready to support Member States with technical expertise throughout the negotiations to help deliver an ambitious, actionable and implementable Political Declaration.
Statement: 2nd April 2026
Member States have a critical opportunity in 2026 to strengthen readiness for future health threats at global, regional, and national levels. Partners of the 100 Days Mission (100DM) reaffirm our shared commitment to reducing the impact of future health emergencies by accelerating the discovery, development, and delivery of diagnostics, therapeutics, and vaccines (DTV) within the first 100 days of an outbreak.
Successful preparedness requires a strong commitment to invest in the necessary tools and technologies to prevent, detect, and respond to infectious disease threats. This requires an enabling policy environment, including the finalisation of the Pandemic Agreement through consensus on a practical, workable, and equitable system for pathogen access and benefit sharing (PABS). It also requires elevating the 2026 UN High-Level Meeting on PPPR, during the high-level week, as a pivotal moment to reinvigorate political action to make progress towards the 100DM.
We call on Member States to use the major political moments of 2026 to adopt a focused set of commitments that will: strengthen a reformed global health architecture that is more equitable, resilient, cohesive, and sustainable; enable more efficient use of resources; build resilient health systems; and accelerate development of, and equitable access to, DTVs.
Priority Policy Asks for Member States
The 100DM partners jointly call for action in the following areas:
- Reaffirm the 100DM as the unifying global goal for PPPR for DTV R&D and manufacturing that supports equitable access and requires global coordination with regional and country ownership.
- Recognise capabilities and operational system readiness as necessary building blocks to enable faster, equitable outbreak response. Moving beyond individual DTV products, this requires ready-to-activate R&D and manufacturing networks, and sustainable, geographically anchored 100DM plans, owned by countries and regions, that are regularly tested or exercised.
- Accelerate access to quality, safe, and effective DTVs during outbreaks through regulatory mechanisms optimised for emergencies, with regulatory capacity-building and collaboration (for example, harmonisation, reliance, and recognition) fostered in advance of the emergency.
- Unify existing PPPR monitoring tools into a coherent, independent mechanism that identifies critical gaps and supports countries in addressing them. In line with wider global health architecture reforms, this mechanism should enable a more efficient and coherent use of resources and clear guidance to countries.
- Adopt portfolio financing approaches that fund diagnostics, therapeutics, and vaccines in an integrated way, incentivising co-development and driving greater synergies across the MCM spectrum.
- Endorse the establishment of a Therapeutics Development Coalition to reinvigorate the bare therapeutics pipeline, strengthen global coordination, and accelerate end-to-end development of promising candidates toward scalable and accessible therapeutics, in alignment with complementary global initiatives such as the Global Coalition for Local and Regional Production, Innovation and Equitable Access.
Key 2026 Moments for Action
Member States should advance these commitments through coordinated action at:
- One Health Summit, 6th – 7th April, Lyon
- World Health Regional Summit, 27th – 29th April, Nairobi
- Africa Forward Summit, 11th – 12th May, Nairobi
- World Health Assembly, 18th – 23rd May, Geneva
- 2026 Global Health Security Conference, 9th-12th June, Kuala Lumpur
- ATACH meeting, July/September
- UN High-Level Meeting on PPPR, September, New York
- World Health Summit, October, Berlin
- International Conference on Public Health in Africa, 1st-5th November, Addis Ababa
The 100 Days Mission partners stand ready to support Member States in delivering these actions and ensuring that 2026 becomes a turning point for global preparedness. By acting together, governments can build a system that protects all countries, uses resources more efficiently, and ensures that life-saving tools reach people within the first 100 days of the next outbreak.
Signatory organisations:
- International Pandemic Preparedness Secretariat (IPPS)
- Coalition for Epidemic Preparedness Innovations (CEPI)
- Foundation for Innovative New Diagnostics (FIND)
- Drugs for Neglected Diseases initiative (DNDi)
- Unitaid